Literature DB >> 19244103

Immune effector cells produce lethal DNA damage in cells treated with a thiopurine.

Ilse Daehn1, Peter Karran.   

Abstract

Azathioprine, a widely used immunosuppressant, is also used in the control of inflammatory disorders. These are characterized by the local accumulation of immune effector cells that produce reactive oxygen species (ROS). The DNA of azathioprine-treated patients contains 6-thioguanine (6-TG), a base analogue that is particularly susceptible to oxidation. Here, we show that 6-TG is vulnerable to ROS produced by chemical oxidants and that cells containing DNA 6-TG are hypersensitive to these oxidants. We also show that 6-TG incorporated into the DNA of macrophages sensitizes them to killing by endogenously produced ROS. ROS generated by macrophages are also a hazard for cocultured nonmacrophage cells containing DNA 6-TG. This bystander vulnerability of cells containing DNA 6-TG to oxidation by ROS generated by immune effector cells has implications for the long-term use of azathioprine in the management of inflammatory disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19244103      PMCID: PMC2658672          DOI: 10.1158/0008-5472.CAN-08-4264

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease.

Authors:  Yukari Masunaga; Keiko Ohno; Ryuichi Ogawa; Masayuki Hashiguchi; Hirotoshi Echizen; Hiroyasu Ogata
Journal:  Ann Pharmacother       Date:  2007-01-02       Impact factor: 3.154

Review 2.  Azathioprine and cyclophosphamide in the treatment of rheumatoid arthritis.

Authors:  K Gaffney; D G Scott
Journal:  Br J Rheumatol       Date:  1998-08

3.  Expression of nitric oxide synthases and formation of nitrotyrosine and reactive oxygen species in inflammatory bowel disease.

Authors:  G Dijkstra; H Moshage; H M van Dullemen; A de Jager-Krikken; A T Tiebosch; J H Kleibeuker; P L Jansen; H van Goor
Journal:  J Pathol       Date:  1998-12       Impact factor: 7.996

4.  Novel DNA lesions generated by the interaction between therapeutic thiopurines and UVA light.

Authors:  Xiaohong Zhang; Graham Jeffs; Xiaolin Ren; Peter O'Donovan; Beatriz Montaner; Conal M Perrett; Peter Karran; Yao-Zhong Xu
Journal:  DNA Repair (Amst)       Date:  2006-12-22

5.  Redox state and O2*- production in neutrophils of Crohn's disease patients.

Authors:  Chiara Biagioni; Fabio Favilli; Serena Catarzi; Tommaso Marcucci; Marilena Fazi; Francesco Tonelli; Maria T Vincenzini; Teresa Iantomasi
Journal:  Exp Biol Med (Maywood)       Date:  2006-02

6.  Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine.

Authors:  Sierra Matula; Victoria Croog; Steven Itzkowitz; Noam Harpaz; Carol Bodian; Sabera Hossain; Thomas Ullman
Journal:  Clin Gastroenterol Hepatol       Date:  2005-10       Impact factor: 11.382

Review 7.  Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer.

Authors:  Peter Karran; Natalie Attard
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

8.  Azathioprine treatment photosensitizes human skin to ultraviolet A radiation.

Authors:  C M Perrett; S L Walker; P O'Donovan; J Warwick; C A Harwood; P Karran; J M McGregor
Journal:  Br J Dermatol       Date:  2008-05-16       Impact factor: 9.302

Review 9.  Cytokines and their relationship to the symptoms and outcome of cancer.

Authors:  Bostjan Seruga; Haibo Zhang; Lori J Bernstein; Ian F Tannock
Journal:  Nat Rev Cancer       Date:  2008-10-10       Impact factor: 60.716

10.  Azathioprine and UVA light generate mutagenic oxidative DNA damage.

Authors:  Peter O'Donovan; Conal M Perrett; Xiaohong Zhang; Beatriz Montaner; Yao-Zhong Xu; Catherine A Harwood; Jane M McGregor; Susan L Walker; Fumio Hanaoka; Peter Karran
Journal:  Science       Date:  2005-09-16       Impact factor: 47.728

View more
  8 in total

1.  Quantification of Thiopurine/UVA-Induced Singlet Oxygen Production.

Authors:  Yazhou Zhang; Ashley N Barnes; Xianchun Zhu; Naomi F Campbell; Ruomei Gao
Journal:  J Photochem Photobiol A Chem       Date:  2011-10-15       Impact factor: 4.291

2.  Guanine sulphinate is a major stable product of photochemical oxidation of DNA 6-thioguanine by UVA irradiation.

Authors:  Xiaolin Ren; Feng Li; Graham Jeffs; Xiaohong Zhang; Yao-Zhong Xu; Peter Karran
Journal:  Nucleic Acids Res       Date:  2009-12-21       Impact factor: 16.971

3.  Direct observation and quantitative characterization of singlet oxygen in aqueous solution upon UVA excitation of 6-thioguanines.

Authors:  Yazhou Zhang; Xianchun Zhu; Joshua Smith; Makeisha T Haygood; Ruomei Gao
Journal:  J Phys Chem B       Date:  2011-02-04       Impact factor: 2.991

4.  Protein oxidation and DNA repair inhibition by 6-thioguanine and UVA radiation.

Authors:  Quentin Gueranger; Feng Li; Matthew Peacock; Annabel Larnicol-Fery; Reto Brem; Peter Macpherson; Jean-Marc Egly; Peter Karran
Journal:  J Invest Dermatol       Date:  2013-11-27       Impact factor: 8.551

5.  DNA breakage and cell cycle checkpoint abrogation induced by a therapeutic thiopurine and UVA radiation.

Authors:  R Brem; F Li; B Montaner; O Reelfs; P Karran
Journal:  Oncogene       Date:  2010-05-03       Impact factor: 9.867

6.  Synthesis and anticancer activity of thiosubstituted purines.

Authors:  Alicja Kowalska; Małgorzata Latocha; Krystian Pluta
Journal:  Med Chem Res       Date:  2015-03-25       Impact factor: 1.965

Review 7.  Review article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases.

Authors:  Aleksandra Piechota-Polanczyk; Jakub Fichna
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-05-06       Impact factor: 3.000

8.  The Inhibitory Effects of 6-Thioguanine and 6-Mercaptopurine on the USP2a Target Fatty Acid Synthase in Human Submaxillary Carcinoma Cells.

Authors:  Chiao-Pei Cheng; Shu-Ting Liu; Yi-Lin Chiu; Shih-Ming Huang; Ching-Liang Ho
Journal:  Front Oncol       Date:  2021-12-10       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.